Camurus setback benefits competitor Indivior

23 January 2018
fda_big

The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for CAM2038, investigational buprenorphine weekly and monthly depot injections, for the treatment of adults with opioid use disorder (OUD), developed by Swedish drugmaker Camurus (STO: CAMX).

The FDA has requested additional information to complete the review. There is no need for new clinical studies and the agency’s requests will be addressed in a timely manner, said the Swedish firm. The North American rights to CAM2038 are licensed to Camurus’ partner, Braeburn Pharmaceutical (Nasdaq: BBRX).

However, what was bad news for Camurus and Braeburn, benefitted UK-based rival Indivior (LSE: INDV), whose drug Sublocade (buprenorphine extended-release) was approved by the FDA in December last year, and pushed the firm’s shares 3.1% higher to 413.5 pence yesterday.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical